09/03/2020 : THERADIAG announces the CE marking for the first four i-Tracker® test kits in its TRACKER® range

Croissy-Beaubourg, March 9, 2020, 6:00 pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has CE marked the first four i-Tracker® test kits…

Continue Reading09/03/2020 : THERADIAG announces the CE marking for the first four i-Tracker® test kits in its TRACKER® range

19/02/2020 : THERADIAG helps establish new WHO international standard for biotherapy monitoring

Croissy-Beaubourg, February 19, 2020, 5:45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, has been actively involved in the establishment and validation of a new World Health…

Continue Reading19/02/2020 : THERADIAG helps establish new WHO international standard for biotherapy monitoring

13/02/2020 : Excellent results generated by new i-Tracker® kits presented at ECCO Congress

TRACKER, a comprehensive range on the market allowing all patients treated with Infliximab to be monitored Croissy-Beaubourg, February 13, 2020, 5:45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics…

Continue Reading13/02/2020 : Excellent results generated by new i-Tracker® kits presented at ECCO Congress